NDT Pharmaceuticals Inc (NDTP): Study of C6 Ceramide NanoLiposome (CNL)...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	3
Posts	848
Boards Moderated	0
Alias Born	11/28/2005

imnot6

Re: None

Tuesday, 03/02/2021 4:48:01 PM

Tuesday, March 02, 2021 4:48:01 PM

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (KNAN2001)

Posted Jan 20, 2021
(Not on the "News" section of Keystone Nano website https://www.keystonenano.com/news-resources)

Study Design

Study Type : Interventional (Clinical Trial) Estimated Enrollment :18 participants
Allocation:N/A
Intervention Model:Single Group Assignment
Intervention Model Description: Single group assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title:Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML) Estimated Study Start Date :February 15, 2021
Estimated Primary Completion Date :December 30, 2021
Estimated Study Completion Date :June 30, 2022

https://clinicaltrials.gov/ct2/show/NCT04716452